Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogenic natural killer cells (Vall d'Hebron Institute of Oncology)
- Development stage
- Unknown
- Lead developer
- Vall d'Hebron Institute of Oncology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of ex-vivo activated allogenic natural killer (NK) cells. Developed by the Vall d'Hebron Institute of Oncology (VHIO), it is being evaluated in combination with the HER2-targeted monoclonal antibodies trastuzumab and pertuzumab for the treatment of refractory metastatic HER2-positive breast cancer. The therapy aims to enhance antibody-dependent cell-mediated cytotoxicity (ADCC), a key mechanism of action for trastuzumab and pertuzumab, by providing a fresh population of activated NK cells to the tumor microenvironment. The treatment protocol typically includes preconditioning with cyclophosphamide to reduce regulatory T cells and post-infusion support with interleukin-2 (IL-2) to promote NK cell survival and activity.
- Other names
- allogenic NK cellsex-vivo activated allogenic NK cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on allogenic natural killer cells (Vall d'Hebron Institute of Oncology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogenic natural killer cells (Vall d'Hebron Institute of Oncology).